Key result
Elevated tPA antigen levels (>10.2 microg/l) independently predicted heart failure-related death or hospitalization in chronic stable heart failure (adjusted HR 2.695; 95% CI 1.233-5.363; p=0.017).
Why the study?
Do elevated tPA antigen levels predict heart failure related deaths or hospitalisations in stable outpatients with chronic heart failure?
Cohort (n=195)
Do elevated tPA antigen levels predict heart failure related deaths or hospitalisations in stable outpatients with chronic heart failure?
Answers are grounded in this paper and cite their sources.
Elevated tPA antigen levels (>10.2 microg/l) independently predict an increased risk of heart failure-related death or hospitalization in stable chronic heart failure patients.
Heart failure is characterised by activation of haemostasis. We sought to explore the prognostic impact of deranged haemostasis in chronic heart failure. In stable, optimally managed outpatients with chronic heart failure, baseline levels of prothrombin fragment F1+2, D-dimer, and tPA and PAI-1 antigens were determined. Clinical follow-up was obtained and the rate of events (heart failure related deaths or hospitalisations) was recorded. We included 195 patients [32.3% female, NYHA class II (66.2%) or III (33.8%), mean age 71 years]. During a median follow up of 693 (interquartile range [IQR] 574-788) days, 63 (30.9%) patients experienced an event; those with an event had higher levels of tPA antigen (median 11.8 [IQR 8.7-14.0] vs. 9.4 [7.9-12.1] microg/l; p = 0.033) and D-dimer (938 [485-1269] vs. 620 [37-1076] microg/l; p = 0.018). However, on Cox multivariate analysis, only tPA levels above optimal cut-off value of 10.2 microg/l (but not D-dimer) emerged as an independent predictor of prognosis (HR(adjusted) 2.695, 95% confidence interval 1.233-5.363; p = 0.017). Our findings suggest that elevated tPA antigen levels are an independent prognostic predictor in patients with chronic stable heart failure.
No takes yet. Share an insight, caveat, or question.
Vene et al. (2009) conducted a cohort in chronic heart failure (n=195). Elevated tPA antigen levels (>10.2 microg/l) vs. tPA antigen levels ≤10.2 microg/l was evaluated on heart failure related deaths or hospitalisations (HR 2.695, 95% CI 1.233-5.363, p=0.017). Elevated tPA antigen levels (>10.2 microg/l) independently predicted heart failure-related death or hospitalization in chronic stable heart failure (adjusted HR 2.695; 95% CI 1.233-5.363; p=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: